Search clinical trials for: eribulin mesylate + erlotinib

Total 3065 results

Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Assiut University

Active, not recruiting

Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Patients Diagnosed as Chronic Meyloid Leukemia

Egypt
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Bladder Cancer

United States
Pamela L. Kunz
Genentech, Inc.

Terminated

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroblastoma | Multiple Endocrine Neoplasia | Pancreatic Neuroendocrine Tumors | Carcinoid Tumors | Adrenal Gland Tumors

United States
SCF Pharma
Integrated Health and Social Services Centres (CISSS) de la Gaspésie; Integrated...

Completed

Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+. (IO3-04)

Inflammation

Canada
George Albert Fisher
Genentech, Inc.

Terminated

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
Hellenic Cooperative Oncology Group

Terminated

Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)

Advanced Non-Small Cell Lung Cancer

Greece
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular... and other conditions

United States
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
UConn Health
National Institute on Aging (NIA); University of Connecticut

Not yet recruiting

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults (Mito-Frail)

Frailty | Aging | Mild Cognitive Impairment

United States
Integrative Skin Science and Research
Actera

Not yet recruiting

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

Hyperpigmentation | Acne | Post-inflammatory Hyperpigmentation
Ball State University

Completed

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

Aging | Endothelial Dysfunction | Arterial Stiffness | Cardiovascular Function

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; OSI Pharmaceuticals

Completed

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer

United States
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
Samsung Medical Center

Completed

Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

Lung Neoplasms | Neoadjuvant Therapy | Erlotinib

Korea, Republic of
Masaryk University

Active, not recruiting

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia (HALF)

Chronic Myeloid Leukemia, Chronic Phase | Withdrawal;Drug

Czechia
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Shanghai Chest Hospital

Unknown

First-line Combination Treatment Based on Anlotinib

Lung Cancer | Advanced Stage

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Chronic Myeloid Leukemia

China
National Cancer Institute (NCI)

Completed

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
SCRI Development Innovations, LLC
Eisai Inc.

Completed

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Metastatic Breast Cancer

United States
Geisinger Clinic
Genentech, Inc.

Terminated

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
University of Alabama at Birmingham
Genentech, Inc.; OSI Pharmaceuticals

Completed

A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma (RAD0503)

Cancer

United States
Hoffmann-La Roche

Completed

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations (BIOTEC)

Carcinoma，Non-Small-Cell Lung

Romania
Daping Hospital and the Research Institute of Surgery...

Completed

Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study

Non-small-cell Lung Cancer | Multiple Brain Metastases

China
Hoffmann-La Roche

Completed

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Russian Federation
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Non-Squamous Non-Small Cell Lung Cancer

Hungary, Latvia, Turkey
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Completed

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

Non-Small Cell Lung Cancer

India
GlaxoSmithKline

Withdrawn

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Cancer
European Organisation for Research and Treatment...

Completed

Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

France, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
National Guard Health Affairs

Suspended

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (REALME)

Non-small Cell Lung Cancer Metastatic

Saudi Arabia
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

Canada
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Breast Cancer

United States
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
Eli Lilly and Company

Completed

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Non-Small Cell Lung Cancer | Malignant Solid Tumor

United States

Search clinical trials for: eribulin mesylate + erlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations